GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biosyent Inc (TSXV:RX) » Definitions » Cyclically Adjusted Price-to-FCF

Biosyent (TSXV:RX) Cyclically Adjusted Price-to-FCF : 22.88 (As of Jun. 07, 2024)


View and export this data going back to 1979. Start your Free Trial

What is Biosyent Cyclically Adjusted Price-to-FCF?

As of today (2024-06-07), Biosyent's current share price is C$9.15. Biosyent's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was C$0.40. Biosyent's Cyclically Adjusted Price-to-FCF for today is 22.88.

The historical rank and industry rank for Biosyent's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

TSXV:RX' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 16.64   Med: 48.53   Max: 318.75
Current: 22.91

During the past years, Biosyent's highest Cyclically Adjusted Price-to-FCF was 318.75. The lowest was 16.64. And the median was 48.53.

TSXV:RX's Cyclically Adjusted Price-to-FCF is ranked better than
61.8% of 322 companies
in the Drug Manufacturers industry
Industry Median: 32.255 vs TSXV:RX: 22.91

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Biosyent's adjusted free cash flow per share data for the three months ended in Mar. 2024 was C$0.080. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is C$0.40 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Biosyent Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Biosyent's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosyent Cyclically Adjusted Price-to-FCF Chart

Biosyent Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 28.73 30.41 27.22 20.10 24.12

Biosyent Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.70 20.23 20.15 24.12 21.78

Competitive Comparison of Biosyent's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Biosyent's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biosyent's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biosyent's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Biosyent's Cyclically Adjusted Price-to-FCF falls into.



Biosyent Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Biosyent's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=9.15/0.4
=22.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biosyent's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Biosyent's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.08/126.2576*126.2576
=0.080

Current CPI (Mar. 2024) = 126.2576.

Biosyent Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.072 99.473 0.091
201409 0.111 99.394 0.141
201412 0.108 98.367 0.139
201503 -0.088 99.789 -0.111
201506 0.051 100.500 0.064
201509 0.062 100.421 0.078
201512 0.091 99.947 0.115
201603 -0.030 101.054 -0.037
201606 0.081 102.002 0.100
201609 0.064 101.765 0.079
201612 0.152 101.449 0.189
201703 0.019 102.634 0.023
201706 0.071 103.029 0.087
201709 0.123 103.345 0.150
201712 0.190 103.345 0.232
201803 0.021 105.004 0.025
201806 0.092 105.557 0.110
201809 0.107 105.636 0.128
201812 0.178 105.399 0.213
201903 -0.023 106.979 -0.027
201906 0.032 107.690 0.038
201909 -0.091 107.611 -0.107
201912 0.354 107.769 0.415
202003 0.028 107.927 0.033
202006 0.176 108.401 0.205
202009 0.167 108.164 0.195
202012 0.147 108.559 0.171
202103 -0.071 110.298 -0.081
202106 0.079 111.720 0.089
202109 0.201 112.905 0.225
202112 0.149 113.774 0.165
202203 -0.011 117.646 -0.012
202206 0.119 120.806 0.124
202209 0.096 120.648 0.100
202212 0.152 120.964 0.159
202303 -0.097 122.702 -0.100
202306 0.249 124.203 0.253
202309 0.198 125.230 0.200
202312 0.052 125.072 0.052
202403 0.080 126.258 0.080

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Biosyent  (TSXV:RX) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Biosyent Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Biosyent's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Biosyent (TSXV:RX) Business Description

Industry
Traded in Other Exchanges
Address
2476 Argentia Road, Suite 402, Toronto, Mississauga, ON, CAN, L5N 6M1
Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Repagyn, and Tibella.
Executives
Peter Douglas Lockhard Director

Biosyent (TSXV:RX) Headlines

No Headlines